...
首页> 外文期刊>Journal of Ethnopharmacology: An Interdisciplinary Journal Devoted to Bioscientific Research on Indigenous Drugs >Hypolipidemic effects of acute and sub-chronic administration of an aqueous extract of Ajuga iva L. whole plant in normal and diabetic rats.
【24h】

Hypolipidemic effects of acute and sub-chronic administration of an aqueous extract of Ajuga iva L. whole plant in normal and diabetic rats.

机译:在正常和糖尿病大鼠中急性和亚慢性给予Ajuga iva L.整个植物的水提取物的降血脂作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Diabetes is often accompanied by lipid abnormalities, which contribute significantly to cardiovascular (CV) morbidity and mortality in diabetic patients. The plant Ajuga iva (L.) Schreiber (Labiatea) is used in the treatment of diabetes in Moroccan folk medicine. Previously, we have demonstrated potent hypoglycemic activity and relatively non-toxic nature of a lyophilized aqueous extract of the whole plant (AI-extract) in normal (normoglycemic) and streptozotocin (STZ)-diabetic rats. In this study, we examined the AI-extract for its possible lipid-lowering activity in normal and STZ-diabetic rats. Taurine (TR) and glibenclamide (GLB) were used as reference substances. As shown previously, the AI-extract (10 mg/kg; oral) reduced plasma glucose levels after acute (single) and sub-chronic (3 weeks) dosing both in normal and diabetic rats. In normal rats, single and repeated oral administration of the AI-extract, at a dose of 10 mg/kg produced a small but significant decrease in plasma CHL levels (P<0.05). A single dose of the AI-extract did not produce a significant change in plasma TG, but sub-chronic dosing (for up to 21 days) caused a significant decrease in plasma TG (P<0.05). In STZ-diabetic rats, a single dose as well as repeated (3 weeks) treatment with the AI-extract produced a significant decrease in plasma CHL (P<0.01), and triglyceride (P<0.01) levels. The AI-extract also prevented weight loss in the diabetic animals. In summary, an aqueous extract of the Ajuga iva whole plant showed hypolipidemic activity, in addition to its hypoglycemic effect in normoglycemic and diabetic rats. In view of the hypoglycemic and hypolipidemic activity, and its relatively non-toxic nature (shown previously), Ajuga iva may be a candidate for development as an anti-diabetic agent in humans. Further studies are warranted to confirm our results and fractionate the AI-extract to isolate and identify the active principle(s), and to determine the exact mechanism(s) of action.
机译:糖尿病经常伴有脂质异常,这极大地增加了糖尿病患者的心血管(CV)发病率和死亡率。 Ajuga iva(L.)Schreiber(Labiatea)植物在摩洛哥民间医学中用于治疗糖尿病。以前,我们已经证明了正常(正常血糖)和链脲佐菌素(STZ)糖尿病大鼠中整个植物的冻干水提取物(AI提取物)的强降血糖活性和相对无毒的性质。在这项研究中,我们检查了AI提取物在正常和STZ糖尿病大鼠中可能的降脂活性。牛磺酸(TR)和格列本脲(GLB)被用作参考物质。如前所示,在正常和糖尿病大鼠中,急性(单次)和亚慢性(3周)给药后,AI提取物(10 mg / kg;口服)降低了血浆葡萄糖水平。在正常大鼠中,以10 mg / kg的剂量单次和重复口服AI提取物可使血浆CHL水平出现小幅但显着的下降(P <0.05)。单一剂量的AI提取物不会使血浆TG发生显着变化,但亚慢性给药(长达21天)会导致血浆TG显着下降(P <0.05)。在STZ糖尿病大鼠中,单次剂量以及AI提取物的重复(3周)治疗可显着降低血浆CHL(P <0.01)和甘油三酸酯(P <0.01)水平。 AI提取物还防止了糖尿病动物的体重减轻。总之,除了在正常血糖和糖尿病大鼠中的降血糖作用外,Ajuga iva整个植物的水提取物还具有降血脂活性。鉴于降血糖和降血脂活性及其相对无毒的性质(如前所示),Ajuga iva可能是发展为抗糖尿病药物的人选。有必要做进一步的研究来确认我们的结果,并对AI提取物进行分级分离,以分离和鉴定有效成分,并确定确切的作用机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号